<?xml version="1.0" ?><!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st June 2018//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_180601.dtd"><PubmedArticleSet><PubmedArticle>    <MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM">        <PMID Version="1">30381917</PMID>        <DateRevised>            <Year>2018</Year>            <Month>11</Month>            <Day>14</Day>        </DateRevised>        <Article PubModel="Print">            <Journal>                <ISSN IssnType="Print">2288-2405</ISSN>                <JournalIssue CitedMedium="Print">                    <Volume>6</Volume>                    <Issue>2</Issue>                    <PubDate>                        <Year>2018</Year>                        <Month>Oct</Month>                    </PubDate>                </JournalIssue>                <Title>Brain tumor research and treatment</Title>                <ISOAbbreviation>Brain Tumor Res Treat</ISOAbbreviation>            </Journal>            <ArticleTitle>A Retrospective Analysis of the Clinical Outcomes of Leptomeningeal Metastasis in Patients with Solid Tumors.</ArticleTitle>            <Pagination>                <MedlinePgn>54-59</MedlinePgn>            </Pagination>            <ELocationID EIdType="doi" ValidYN="Y">10.14791/btrt.2018.6.e12</ELocationID>            <Abstract>                <AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Leptomeningeal metastasis (LM) is an uncommon, but devastating complication of advanced cancer and has no standard treatment. Herein, we analyzed the clinical characteristics and outcomes of patients with solid tumors who were diagnosed with LM.</AbstractText>                <AbstractText Label="METHODS" NlmCategory="METHODS">Between January 2007 and December 2017, we retrospectively analyzed the medical records of patients with solid tumors who were diagnosed with LM.</AbstractText>                <AbstractText Label="RESULTS" NlmCategory="RESULTS">A total of 58 patients were enrolled in this study. The median age of patients was 51 years (range, 27-72 years), and 62.1% had a poor Eastern Cooperative Oncology Group (ECOG) performance status (PS) (&gt;2). The common types of primary tumor were breast cancer (39.7%), gastric cancer (25.9%), and non-small cell lung cancer (20.7%). Forty-two patients (72.4%) were diagnosed with LM by MRI of the brain and/or spine and cerebrospinal fluid (CSF) analysis, 14 were diagnosed by CSF analysis alone, and 2 were diagnosed by MRI alone. Treatments for LM were performed in 53 patients (91.4%), and best supportive care was provided for 5 patients (8.6%). Intrathecal chemotherapy, radiotherapy, and systemic chemotherapy were administered in 43 (74.1%), 17 (29.3%), and 24 (41.4%) patients, respectively. The median overall survival of the entire cohort was 2.4 months (95% confidence interval, 1.0-3.7). In the analysis of prognostic factors for survival, a good ECOG PS (≤2), administration of systemic chemotherapy after LM diagnosis, and a prior history of brain radiation were associated with prolonged survival.</AbstractText>                <AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Although the prognosis of LM in patients with solid tumors is poor, systemic chemotherapy might improve survival in selected patients with a good PS.</AbstractText>                <CopyrightInformation>Copyright © 2018 The Korean Brain Tumor Society, The Korean Society for Neuro-Oncology, and The Korean Society for Pediatric Neuro-Oncology.</CopyrightInformation>            </Abstract>            <AuthorList CompleteYN="Y">                <Author ValidYN="Y">                    <LastName>Kim</LastName>                    <ForeName>Hyojeong</ForeName>                    <Initials>H</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Hemato-Oncology, Pusan University Hospital, Busan, Korea.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Lee</LastName>                    <ForeName>Eun Mi</ForeName>                    <Initials>EM</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Internal Medicine, Kosin University Gaspel Hospital, Busan, Korea. byule00@hanmail.net.</Affiliation>                    </AffiliationInfo>                </Author>            </AuthorList>            <Language>eng</Language>            <PublicationTypeList>                <PublicationType UI="D016428">Journal Article</PublicationType>            </PublicationTypeList>        </Article>        <MedlineJournalInfo>            <Country>Korea (South)</Country>            <MedlineTA>Brain Tumor Res Treat</MedlineTA>            <NlmUniqueID>101627407</NlmUniqueID>            <ISSNLinking>2288-2405</ISSNLinking>        </MedlineJournalInfo>        <CommentsCorrectionsList>            <CommentsCorrections RefType="Cites">                <RefSource>J Neurol Sci. 2004 Aug 30;223(2):167-78</RefSource>                <PMID Version="1">15337619</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>J Thorac Oncol. 2015 Dec;10(12):1754-61</RefSource>                <PMID Version="1">26334749</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Eur J Cancer. 2004 Dec;40(18):2726-33</RefSource>                <PMID Version="1">15571954</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>J Cancer Res Clin Oncol. 2010 Nov;136(11):1729-35</RefSource>                <PMID Version="1">20204406</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>J Neurooncol. 2013 Nov;115(2):285-91</RefSource>                <PMID Version="1">24000114</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Arch Neurol. 2009 Jan;66(1):74-8</RefSource>                <PMID Version="1">19139302</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Eur J Cancer. 2016 Mar;56:107-114</RefSource>                <PMID Version="1">26841095</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Cancer. 1982 Feb 15;49(4):759-72</RefSource>                <PMID Version="1">6895713</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Ann Oncol. 2004;15 Suppl 4:iv285-91</RefSource>                <PMID Version="1">15477323</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>J Korean Med Sci. 2014 Aug;29(8):1094-101</RefSource>                <PMID Version="1">25120319</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>J Neurooncol. 2005 Oct;75(1):85-99</RefSource>                <PMID Version="1">16215819</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>ScientificWorldJournal. 2013 Dec 19;2013:248072</RefSource>                <PMID Version="1">24453817</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Clin Neurol Neurosurg. 2013 Jan;115(1):19-25</RefSource>                <PMID Version="1">22534095</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Expert Opin Pharmacother. 2005 Jun;6(7):1115-25</RefSource>                <PMID Version="1">15957966</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Neurosurgery. 2003 Feb;52(2):324-29; discussion 330</RefSource>                <PMID Version="1">12535360</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>J Clin Neurosci. 2016 May;27:130-7</RefSource>                <PMID Version="1">26778048</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>J Neurooncol. 2009 Jun;93(2):205-12</RefSource>                <PMID Version="1">19043775</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Ann Neurol. 1995 Jul;38(1):51-7</RefSource>                <PMID Version="1">7611725</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Adv Neurol. 1978;19:579-92</RefSource>                <PMID Version="1">570349</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Neurology. 2010 May 4;74(18):1449-54</RefSource>                <PMID Version="1">20439847</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Cancer. 1998 Feb 15;82(4):733-9</RefSource>                <PMID Version="1">9477107</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Int J Mol Sci. 2016 Jul 05;17(7):</RefSource>                <PMID Version="1">27399673</PMID>            </CommentsCorrections>        </CommentsCorrectionsList>        <KeywordList Owner="NOTNLM">            <Keyword MajorTopicYN="N">Cerebrospinal fluid</Keyword>            <Keyword MajorTopicYN="N">Chemotherapy</Keyword>            <Keyword MajorTopicYN="N">Leptomeningeal carcinomatosis</Keyword>        </KeywordList>        <CoiStatement>The authors have no financial conflicts of interest.</CoiStatement>    </MedlineCitation>    <PubmedData>        <History>            <PubMedPubDate PubStatus="received">                <Year>2018</Year>                <Month>08</Month>                <Day>18</Day>            </PubMedPubDate>            <PubMedPubDate PubStatus="revised">                <Year>2018</Year>                <Month>09</Month>                <Day>14</Day>            </PubMedPubDate>            <PubMedPubDate PubStatus="accepted">                <Year>2018</Year>                <Month>09</Month>                <Day>18</Day>            </PubMedPubDate>            <PubMedPubDate PubStatus="entrez">                <Year>2018</Year>                <Month>11</Month>                <Day>2</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="pubmed">                <Year>2018</Year>                <Month>11</Month>                <Day>2</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="medline">                <Year>2018</Year>                <Month>11</Month>                <Day>2</Day>                <Hour>6</Hour>                <Minute>1</Minute>            </PubMedPubDate>        </History>        <PublicationStatus>ppublish</PublicationStatus>        <ArticleIdList>            <ArticleId IdType="pubmed">30381917</ArticleId>            <ArticleId IdType="pii">6.54</ArticleId>            <ArticleId IdType="doi">10.14791/btrt.2018.6.e12</ArticleId>            <ArticleId IdType="pmc">PMC6212684</ArticleId>        </ArticleIdList>    </PubmedData></PubmedArticle></PubmedArticleSet>